Prognostic Factors in Urothelial Carcinoma of the Bladder
Authors:
- Donna E. HanselDHDonna E. Hansel
- 1 March 2015
- journal article
- review article
- Published by Wolters Kluwer Health in Advances in Anatomic Pathology
- Vol. 22 (2) , 102-112
Abstract
Histologic characterization of urothelial carcinoma remains the most important factor for determining a patient's prognosis and treatment regimen. However, challenges remain in accurately staging and grading many tumors, and substaging remains controversial. Recently, significant insight has been gained into the molecular pathogenesis of bladder cancer that may aid in further characterizing urothelial carcinoma. Many molecular biomarkers have been clinically validated, and some have been shown to provide more prognostic information than histology alone. In addition, a subset of these markers may even represent targets for molecular therapy. Here, we review histologic staging and grading of urothelial carcinoma, as well as discuss many of the clinically relevant molecular markers. As each urothelial carcinoma likely represents a unique biological entity, the need for complete histologic and molecular characterization of these tumors is necessary as we enter the age of personalized medicine.Keywords
This publication has 76 references indexed in Scilit:
- Plasmacytoid variant of bladder cancer defines patients with poor prognosis if treated with cystectomy and adjuvant cisplatin-based chemotherapyBMC Cancer, 2013
- The 1973 WHO Classification Is More Suitable than the 2004 WHO Classification for Predicting Prognosis in Non-Muscle-Invasive Bladder CancerPLOS ONE, 2012
- High epidermal growth factor receptor immunohistochemical expression in urothelial carcinoma of the bladder is not associated with EGFR mutations in exons 19 and 21: a study using formalin-fixed, paraffin-embedded archival tissuesHuman Pathology, 2012
- Emerging Critical Role of Molecular Testing in Diagnostic Genitourinary PathologyArchives of Pathology & Laboratory Medicine, 2012
- Expression of cell cycle-associated proteins in non-muscle-invasive bladder cancer: Correlation with intravesical recurrence following transurethral resectionUrologic Oncology: Seminars and Original Investigations, 2011
- Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladderNature Genetics, 2011
- Mammalian Target of Rapamycin (mTOR) Regulates Cellular Proliferation and Tumor Growth in Urothelial CarcinomaThe American Journal of Pathology, 2010
- Utility of a dual immunostain cocktail comprising of p53 and CK20 to aid in the diagnosis of non-neoplastic and neoplastic bladder biopsiesDiagnostic Pathology, 2009
- Molecular Grading of Urothelial Cell Carcinoma With Fibroblast Growth Factor Receptor 3 and MIB-1 is Superior to Pathologic Grade for the Prediction of Clinical OutcomeJournal of Clinical Oncology, 2003
- Frequent FGFR3 Mutations in Papillary Non-Invasive Bladder (pTa) TumorsThe American Journal of Pathology, 2001